Skip to content

Study · Randomized controlled trial · n = 311 · 2001

4 results

Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).

de Jong D, Macklon NS, Eijkemans MJ, Mannaerts BM, Coelingh Bennink HJ, Fauser BC

Fertility and sterility1 Apr 2001Cited by 31 (Europe PMC)

PMID11287020 (opens in a new tab)DOI10.1016/s0015-0282(00)01789-1 (opens in a new tab)PepBankPUB-11287020
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In IVF patients, follicular growth was similar across ganirelix dose groups.

    In plain wordsIn IVF patients, follicular growth was similar across ganirelix doses.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedFollicular growth
    Study

    n = 311

    Comparator
    Other ganirelix doses
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.0625-2.0 mg/dAs given in this study (human).

    Source sentences

    Summary
    In 311 patients, similar follicular growth was observed in all treatment groups.
    5 context sentences
    Summary · context
    Randomized controlled multicenter trial.
    Summary · context
    Three hundred and twenty-nine IVF patients.
    Summary · context
    Ovarian stimulation for IVF with recombinant FSH starting on cycle day 2.
    Summary · context
    From cycle day 7 onwards, cotreatment was provided with 0.0625, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/d GnRH antagonist.
    Summary · context
    Follicular growth was unaffected by the dose of GnRH antagonist.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In IVF patients, late follicular LH decreased with increasing ganirelix dose (P<0.05).

    In plain wordsIn IVF patients, higher ganirelix doses reduced late follicular LH more than lower doses.

    Peptide
    Ganirelix
    Outcome
    DecreaseLate follicular LH
    Study

    n = 311

    Comparator
    Other ganirelix doses
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.0625-2.0 mg/dAs given in this study (human).

    Measurements

    P value, dose-related decrease in late follicular lh
    < 0.05 unitless
    between GnRH antagonist dose groups

    Source sentences

    Summary
    Late follicular phase LH, androstenedione (AD), and E(2) levels showed a GnRH antagonist dose-related decrease (P<0.05).
    4 context sentences
    Summary · context
    Randomized controlled multicenter trial.
    Summary · context
    Three hundred and twenty-nine IVF patients.
    Summary · context
    Ovarian stimulation for IVF with recombinant FSH starting on cycle day 2.
    Summary · context
    From cycle day 7 onwards, cotreatment was provided with 0.0625, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/d GnRH antagonist.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In IVF patients, late follicular androstenedione decreased with increasing ganirelix dose (P<0.05).

    In plain wordsIn IVF patients, higher ganirelix doses reduced late follicular androstenedione more than lower doses.

    Peptide
    Ganirelix
    Outcome
    DecreaseLate follicular androstenedione
    Study

    n = 311

    Comparator
    Other ganirelix doses
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.0625-2.0 mg/dAs given in this study (human).

    Measurements

    P value, dose-related decrease in late follicular androstenedione
    < 0.05 unitless
    between GnRH antagonist dose groups

    Source sentences

    Summary
    Late follicular phase LH, androstenedione (AD), and E(2) levels showed a GnRH antagonist dose-related decrease (P<0.05).
    4 context sentences
    Summary · context
    Randomized controlled multicenter trial.
    Summary · context
    Three hundred and twenty-nine IVF patients.
    Summary · context
    Ovarian stimulation for IVF with recombinant FSH starting on cycle day 2.
    Summary · context
    From cycle day 7 onwards, cotreatment was provided with 0.0625, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/d GnRH antagonist.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In IVF patients, late follicular E(2) decreased with increasing ganirelix dose (P<0.05).

    In plain wordsIn IVF patients, higher ganirelix doses reduced late follicular E(2) more than lower doses.

    Peptide
    Ganirelix
    Outcome
    DecreaseLate follicular E(2)
    Study

    n = 311

    Comparator
    Other ganirelix doses
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.0625-2.0 mg/dAs given in this study (human).

    Measurements

    P value, dose-related decrease in late follicular e(2)
    < 0.05 unitless
    between GnRH antagonist dose groups

    Source sentences

    Summary
    Late follicular phase LH, androstenedione (AD), and E(2) levels showed a GnRH antagonist dose-related decrease (P<0.05).
    5 context sentences
    Summary · context
    Increasing GnRH antagonist doses exhibited additional suppressive action on E(2) levels.
    Summary · context
    Randomized controlled multicenter trial.
    Summary · context
    Three hundred and twenty-nine IVF patients.
    Summary · context
    Ovarian stimulation for IVF with recombinant FSH starting on cycle day 2.
    Summary · context
    From cycle day 7 onwards, cotreatment was provided with 0.0625, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/d GnRH antagonist.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.